09:28 AM EDT, 10/17/2025 (MT Newswires) -- AbbVie ( ABBV ) said Friday it has closed the acquisition of Gilgamesh Pharmaceuticals' lead investigational candidate bretisilocin.
Bretisilocin is a psychedelic compound in phase 2 clinical development for the treatment of patients with moderate to severe major depressive disorder, AbbVie ( ABBV ) said.